{ "model": { "rank": 5038, "code": "thing-q179452", "model_id": "vr.tr.dl-amphetamine", "name": "DL-amphetamine", "purpose": "Enable an AI agent to recognise DL-amphetamine, assess the identity and condition of a material sample, and determine which handling or use decisions require further evidence.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.MAT", "industry": "", "version": "", "url": "/models/thing/q179452/", "tier": 2, "score": 70, "payload": { "layer": "wikidata", "aliases": [ "dextroamphetamine", "(R)-amphetamine", "DOx" ], "aliasCount": 3, "merged": 3, "knownIn": 70, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q179452", "url": "https://www.wikidata.org/wiki/Q179452", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-09T21:31:58Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 20.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a08814-c9a7-76b0-93a6-3eab9a3a1f9b\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: DL-amphetamine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 005: 1001 ", "usd": 0, "recall": true }, "codex": { "seconds": 60.4, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a08814-c997-7702-bd5b-ba4c5f2e1b9a\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: DL-amphetamine\nRegistry id: vr.tr.dl-amphetamine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (no" } } }, "metaModel": { "id": "THING-Q179452", "registryId": "vr.tr.dl-amphetamine", "name": "DL-amphetamine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q179452/", "model": { "registry_id": "vr.tr.dl-amphetamine", "name": "DL-amphetamine", "purpose": "Enable an AI agent to recognise DL-amphetamine, assess the identity and condition of a material sample, and determine which handling or use decisions require further evidence.", "definition": "DL-amphetamine is racemic amphetamine, an equimolar mixture of the (S)-(+)- and (R)-(−)-enantiomers of 1-phenylpropan-2-amine, a synthetic sympathomimetic central nervous system stimulant.", "scope_statement": "This model owns DL-amphetamine as the racemic substance identity and the evidence needed to characterise samples attributed to it, distinguishing stereochemical composition, free-base or salt form, purity, condition, and applicable controls from finished products and human use.", "in_scope": [ "Racemic identity and measured proportions of the two amphetamine enantiomers", "Free-base identity and explicit relationships to salt, hydrate, or solvate forms", "Sample composition, impurities, concentration, and analytical evidence", "Physical state and measured properties under stated conditions", "Form-specific hazards, storage condition, and jurisdiction-specific controlled-substance status" ], "out_of_scope": [ "Dextroamphetamine or levoamphetamine as separately modelled substances", "Finished medicines and mixed-amphetamine formulations as products", "Clinical diagnosis, prescribing, dosing, and patient outcomes", "Synthesis, extraction, or illicit manufacturing procedures", "Drug-market activity and substance-use behaviour" ], "distinguishing_features": [ "Require evidence of approximately equal proportions of the two amphetamine enantiomers within a stated analytical tolerance; the label 'amphetamine' alone does not establish DL identity.", "Distinguish racemic amphetamine from an enantiomer-enriched mixture, including products whose amphetamine components are not present in equal enantiomeric proportions.", "Distinguish free base from an amphetamine salt using counterion and composition evidence rather than treating their identifiers and physical constants as interchangeable.", "Confirm amphetamine molecular identity independently of stereochemical composition; a broad stimulant or amphetamine-class screening result is insufficient.", "Distinguish a characterised substance sample from a tablet, solution, or other formulated product containing it." ], "characteristics": [ { "name": "Molecular identity evidence", "kind": "relation", "unit_or_values": "Sample linked to structure assignment, analytical method, reference material, and report", "why_it_matters": "Prevents chemically related substances or broad screening positives from being accepted as DL-amphetamine." }, { "name": "Enantiomeric composition", "kind": "measurement", "unit_or_values": "Mole fraction or mol% of each enantiomer, with assignment convention, uncertainty, and method", "why_it_matters": "Determines whether the sample supports a racemic identity or requires a different composition description." }, { "name": "Chemical form", "kind": "category", "unit_or_values": "Free base; identified salt with stoichiometry; hydrate or solvate where established; unresolved", "why_it_matters": "Controls which identifiers, mass basis, physical properties, and hazard evidence apply." }, { "name": "Amphetamine content", "kind": "measurement", "unit_or_values": "Mass fraction, molar concentration, or mass concentration, explicitly stated as free-base equivalent or identified-form content", "why_it_matters": "Makes results comparable without confusing salt mass, solution concentration, and active-moiety content." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Identified and unidentified components in appropriate concentration units, with detection and quantification limits", "why_it_matters": "Separates chemical purity from enantiomeric composition and exposes limitations in sample suitability." }, { "name": "Physical state and thermal properties", "kind": "measurement", "unit_or_values": "Observed phase; transition temperatures in °C or K; pressure in kPa; chemical form and test conditions", "why_it_matters": "Prevents constants reported for one form or condition from being applied to another." }, { "name": "Sample integrity", "kind": "state", "unit_or_values": "Within documented acceptance criteria; suspected change; confirmed change; unassessed", "why_it_matters": "Connects storage history and reanalysis to whether earlier characterisation remains usable." }, { "name": "Regulatory identity and action status", "kind": "relation", "unit_or_values": "Links to verified identifiers and dated jurisdictional determinations for possession, transfer, transport, analysis, or disposal", "why_it_matters": "Chemical identity alone does not establish whether a particular actor may perform a particular action." } ], "affordances": [ "Compare sample evidence with the proposed racemic identity and flag unresolved stereochemistry.", "Select reference records and property evidence matching the sample's exact chemical form.", "Compare assay results after reconciling free-base-equivalent, salt-content, and concentration bases.", "Assess whether analytical quality and storage history support a stated laboratory use.", "Identify the current hazard documentation and authorisation evidence required before handling, transfer, or disposal." ] }, "sources": [], "structure": { "bundles": [ { "id": "racemic-identity-and-boundaries", "name": "Racemic identity and boundaries", "description": "Establish what DL-amphetamine denotes and which samples support that designation.", "rationale": "The distinguishing feature is stereochemical composition, which cannot be inferred from an unspecified amphetamine label.", "layers": [ { "id": "molecular-and-stereochemical-identity", "name": "Molecular and stereochemical identity", "description": "Separate confirmation of amphetamine structure from confirmation of a racemic composition.", "findings": [ { "id": "racemate-evidence", "name": "Evidence required for DL identity", "description": "Record molecular identification and enantiomer-resolving evidence separately, with an explicit tolerance for accepting the racemic designation.", "questions": [ { "text": "What evidence identifies the material as amphetamine rather than another related compound?", "kind": "definition", "id": "racemate-evidence-q01" }, { "text": "What measured enantiomer proportions, uncertainty, and acceptance tolerance support calling this sample DL-amphetamine?", "kind": "measurement", "id": "racemate-evidence-q02" } ] } ] }, { "id": "chemical-form-and-registry-boundary", "name": "Chemical form and registry boundary", "description": "Resolve free-base, salt, and product references without silently changing the registered concept.", "findings": [ { "id": "form-specific-identity", "name": "Form-specific identity mapping", "description": "Attach identifiers to the exact entity they describe and preserve the distinction between racemic substance identity and a particular salt or formulation.", "questions": [ { "text": "Does vr.tr.dl-amphetamine denote the racemic free base specifically, or does its source record explicitly include salt forms?", "kind": "boundary", "id": "form-specific-identity-q01" }, { "text": "Which verified CAS, PubChem, and EC records match the intended stereochemistry and chemical form, and which describe neighbouring entities?", "kind": "provenance", "id": "form-specific-identity-q02" } ] } ] } ] }, { "id": "sample-composition-and-analytical-confidence", "name": "Sample composition and analytical confidence", "description": "Describe what a sample contains and how strongly the measurements support that description.", "rationale": "Racemic composition, amphetamine content, and chemical purity are different properties and must not substitute for one another.", "layers": [ { "id": "content-and-impurities", "name": "Content and impurities", "description": "Record quantitative composition on an explicit chemical and sample basis.", "findings": [ { "id": "assay-basis-and-purity", "name": "Assay basis and purity", "description": "Distinguish amphetamine content from counterion, water, solvent, excipient, and impurity contributions to sample mass.", "questions": [ { "text": "Is the reported content expressed as free-base equivalent, identified salt, dry material, or material as received?", "kind": "measurement", "id": "assay-basis-and-purity-q01" }, { "text": "Which impurities, residual solvents, and water content were measured, and what remains below detection or unidentified?", "kind": "measurement", "id": "assay-basis-and-purity-q02" } ] } ] }, { "id": "method-and-reference-evidence", "name": "Method and reference evidence", "description": "Connect molecular and chiral measurements to methods, standards, and the actual sample tested.", "findings": [ { "id": "analytical-fitness", "name": "Analytical fitness for identity decisions", "description": "Record whether the analytical evidence can establish molecular identity, resolve enantiomers, and quantify content for the intended decision.", "questions": [ { "text": "Which methods and reference materials support the molecular assignment and the assignment of each enantiomer?", "kind": "provenance", "id": "analytical-fitness-q01" }, { "text": "Do method selectivity, uncertainty, and sample traceability support the proposed acceptance decision, or is confirmatory analysis required?", "kind": "action", "id": "analytical-fitness-q02" } ] } ] } ] }, { "id": "physical-form-and-sample-integrity", "name": "Physical form and sample integrity", "description": "Assess properties and changes of the identified DL-amphetamine material under documented conditions.", "rationale": "Physical constants and storage judgements are unreliable when free base, salts, solutions, and altered samples are conflated.", "layers": [ { "id": "condition-dependent-properties", "name": "Condition-dependent properties", "description": "Associate phase and property measurements with the exact form, composition, and conditions.", "findings": [ { "id": "applicable-property-records", "name": "Applicable physical-property records", "description": "Use melting, boiling, solubility, and other property evidence only when its material identity and measurement conditions fit the sample.", "questions": [ { "text": "What phase is observed at the recorded temperature, and what chemical form and solvent composition does that observation describe?", "kind": "measurement", "id": "applicable-property-records-q01" }, { "text": "Which thermal or solubility values are supported for this exact form, with units, pressure or solvent conditions, and any reported decomposition?", "kind": "provenance", "id": "applicable-property-records-q02" } ] } ] }, { "id": "storage-history-and-change", "name": "Storage history and change", "description": "Determine whether sample history affects the continued validity of its characterisation.", "findings": [ { "id": "continued-sample-suitability", "name": "Continued sample suitability", "description": "Link packaging, exposure history, and observed changes to documented stability evidence and criteria for reanalysis.", "questions": [ { "text": "What storage and packaging conditions are documented for this form, and what deviations occurred for this sample?", "kind": "provenance", "id": "continued-sample-suitability-q01" }, { "text": "What observed change or elapsed interval requires rechecking content, impurity profile, or enantiomeric composition before further use?", "kind": "action", "id": "continued-sample-suitability-q02" } ] } ] } ] }, { "id": "hazards-and-permitted-material-actions", "name": "Hazards and permitted material actions", "description": "Connect the characterised material to applicable hazard evidence and legal conditions for specific actions.", "rationale": "DL-amphetamine requires decisions that account for exact material form, exposure circumstances, jurisdiction, and the authority of the actor.", "layers": [ { "id": "form-specific-hazard-evidence", "name": "Form-specific hazard evidence", "description": "Identify hazard information applicable to the substance form and sample composition.", "findings": [ { "id": "hazard-classification-and-exposure-basis", "name": "Hazard classification and exposure basis", "description": "Record the source and applicability of classifications, handling requirements, and any established occupational exposure limits without borrowing them from an unmatched product.", "questions": [ { "text": "Which current safety data and GHS classification apply to this chemical form, concentration, and jurisdiction?", "kind": "provenance", "id": "hazard-classification-and-exposure-basis-q01" }, { "text": "Is an authoritative occupational exposure limit established for this material, and what units and averaging period apply if one exists?", "kind": "measurement", "id": "hazard-classification-and-exposure-basis-q02" } ] } ] }, { "id": "jurisdiction-and-authorised-action", "name": "Jurisdiction and authorised action", "description": "Assess a proposed material action against dated legal and institutional evidence.", "findings": [ { "id": "action-specific-authority", "name": "Action-specific authority", "description": "Treat controlled-substance status and actor permissions as evidence tied to a jurisdiction, date, chemical scope, and proposed action.", "questions": [ { "text": "Which current legal provisions cover racemic amphetamine and the particular salt or preparation in the relevant jurisdictions?", "kind": "provenance", "id": "action-specific-authority-q01" }, { "text": "What verified authorisation, custody records, and procedural requirements apply to the proposed possession, analysis, transfer, transport, or disposal?", "kind": "action", "id": "action-specific-authority-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information, without source consultation.", "Confirm whether the registry entry denotes the free base specifically or racemic amphetamine across salt forms before assigning additional identifiers or physical constants.", "Researchers should verify salt-specific purity, physical properties, hazard classifications and current jurisdiction-specific controls." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Racemic amphetamine free base", "Racemic amphetamine sulfate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "300-62-9", "note": "Identifies racemic amphetamine free base; salts have separate identifiers." }, { "scheme": "Molecular formula", "value_or_pattern": "C9H13N", "note": "Formula of the free base; does not distinguish enantiomers or their proportions." }, { "scheme": "Chemical nomenclature", "value_or_pattern": "rac-1-phenylpropan-2-amine", "note": "The racemic designation specifies equal proportions of the two enantiomers." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Pharmaceutical stimulant ingredient in salt form, with availability and authorized indications depending on jurisdiction and formulation.", "Research reference substance for studying stimulant pharmacology and stereochemical differences." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of free base", "typical_range": "135.21", "unit": "g/mol" }, { "quantity": "Enantiomeric composition of the ideal racemate", "typical_range": "50% (S)-amphetamine and 50% (R)-amphetamine", "unit": "mol%" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Can cause dependence and compulsive use.", "Excessive exposure can cause severe cardiovascular and central nervous system toxicity.", "Can cause insomnia, agitation and appetite suppression.", "Severe intoxication can involve hyperthermia, seizures or psychosis.", "Confusing free-base mass with salt mass, or racemic material with an enantiomer-enriched preparation, can produce composition and potency errors." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Amphetamine", "difference": "The broader name may leave stereochemical composition unspecified; DL-amphetamine explicitly denotes the racemate." }, { "name": "Dextroamphetamine", "difference": "Dextroamphetamine is the (S)-(+)-enantiomer alone rather than an equimolar mixture." }, { "name": "Levoamphetamine", "difference": "Levoamphetamine is the (R)-(−)-enantiomer alone rather than an equimolar mixture." }, { "name": "Methamphetamine", "difference": "Methamphetamine has an additional methyl substituent on nitrogen and is a different chemical substance." }, { "name": "Mixed amphetamine salts", "difference": "This names a pharmaceutical mixture of salts; its enantiomer ratio must be established from the formulation and need not be racemic." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of DL-amphetamine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the originating registry record define DL-amphetamine strictly as the racemic free base, and does an existing Vercy world model already own that concept?", "Which CAS number, PubChem CID, and EC number are verified matches for the registry's exact stereochemical and chemical-form scope?", "What analytical tolerance and reference convention should govern acceptance of a sample as racemic rather than enantiomer-enriched?", "Which physical constants, stability evidence, and impurity acceptance criteria are adequately supported for each included material form?", "Which current jurisdiction-specific classifications, exposure limits if any, and controlled-substance provisions apply to the intended material actions?" ], "statistics": { "bundles": 5, "layers": 9, "findings": 15, "questions": 23 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "chemical substance or material", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a DL-amphetamine, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise DL-amphetamine, assess the identity and condition of a material sample, and determine which handling or use decisions require further evidence.", "characteristics": { "substance": "material", "origin": "natural", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured", "consumed or used up" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: dextroamphetamine, (R)-amphetamine, DOx.", "3 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 70 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a DL-amphetamine, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state", "use it up, and then need more of it" ], "howItIsRecognised": [ "Not recognisable by sight in any reliable way. Appearance varies with grade, form and additives; identification is by label, by documentation, or by assay." ], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "dextroamphetamine", "(R)-amphetamine", "DOx" ] } ], "standing": "Described in 70 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 3 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one DL-amphetamine from another, and a DL-amphetamine from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a DL-amphetamine sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a DL-amphetamine from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a DL-amphetamine is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a DL-amphetamine is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a DL-amphetamine is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a DL-amphetamine is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a DL-amphetamine is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a DL-amphetamine is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a DL-amphetamine passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a DL-amphetamine between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a DL-amphetamine, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a DL-amphetamine is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "use-and-operation", "name": "Use and operation", "description": "What can be done with a DL-amphetamine and what it takes to do it.", "rationale": "An agent that can recognise a thing but not act on it has only half a model.", "layers": [ { "id": "intended-use", "name": "Intended use and function", "description": "What a DL-amphetamine is for, and what it is used for anyway.", "findings": [ { "id": "function-and-purpose", "name": "Function, purpose and misuse", "description": "The function a DL-amphetamine performs and the uses that fall outside it.", "questions": [ { "id": "function-and-purpose-q01", "text": "What identifies and describes the use of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "function-and-purpose-q02", "text": "Who or what asserted this about the use of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "function-and-purpose-q03", "text": "What may an agent decide or do once the use of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "handling-and-procedure", "name": "Handling and procedure", "description": "The steps, skills and tools involved in using a DL-amphetamine.", "findings": [ { "id": "procedures-and-skills", "name": "Procedures, skills and required tools", "description": "What an agent needs before it can act on a DL-amphetamine at all.", "questions": [ { "id": "procedures-and-skills-q01", "text": "What identifies and describes handling a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "procedures-and-skills-q02", "text": "Who or what asserted this about handling a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "procedures-and-skills-q03", "text": "What may an agent decide or do once handling a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "supply-and-consumption", "name": "Supply and consumption", "description": "Quantities, rates and what running out means.", "findings": [ { "id": "consumption-and-stock", "name": "Consumption, stock and replenishment", "description": "How much of a DL-amphetamine there is and how fast it goes.", "questions": [ { "id": "consumption-and-stock-q01", "text": "What identifies and describes the supply of a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "consumption-and-stock-q02", "text": "Who or what asserted this about the supply of a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "consumption-and-stock-q03", "text": "What may an agent decide or do once the supply of a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "composition-and-identity", "name": "Composition, grade and chemical identity", "description": "What DL-amphetamine is made of and how pure the thing in hand is.", "rationale": "Grade decides what a substance may be used for, so a model that records only the name cannot support any decision about use.", "layers": [ { "id": "chemical-identity", "name": "Chemical identity", "description": "Formula, structure and the registry numbers that name it unambiguously.", "findings": [ { "id": "identity-record", "name": "Identity and registry numbers", "description": "What identifies this substance across suppliers and regulators.", "questions": [ { "id": "identity-record-q01", "text": "What formula, structure and registry identifiers name DL-amphetamine unambiguously?", "kind": "definition" }, { "id": "identity-record-q02", "text": "Which related substances share a name in common use but not an identifier?", "kind": "boundary" } ] } ] }, { "id": "grade-and-impurities", "name": "Grade, purity and impurities", "description": "The specification a batch meets and what else is in it.", "findings": [ { "id": "specification", "name": "Specification and assay", "description": "How purity is stated and measured, and which impurities matter.", "questions": [ { "id": "specification-q01", "text": "What grades of DL-amphetamine exist, how is purity assayed, and which impurities are limited?", "kind": "measurement" }, { "id": "specification-q02", "text": "Which use requires which grade, and what happens when a lower grade is substituted?", "kind": "action" } ] } ] } ] }, { "id": "properties-and-behaviour", "name": "Properties and behaviour", "description": "How DL-amphetamine behaves under conditions an agent can measure or change.", "rationale": "Physical constants are the part of a substance model that transfers between contexts, and each needs its unit and its conditions.", "layers": [ { "id": "physical-constants", "name": "Physical constants", "description": "Values that hold for the pure substance, with their conditions.", "findings": [ { "id": "constants-record", "name": "Constants and conditions", "description": "The quantities worth recording and the state they apply in.", "questions": [ { "id": "constants-record-q01", "text": "What are the defining physical constants of DL-amphetamine, in what units and under what conditions?", "kind": "measurement" }, { "id": "constants-record-q02", "text": "Which of these values change with grade or form rather than being fixed?", "kind": "boundary" } ] } ] }, { "id": "stability-and-reactivity", "name": "Stability and reactivity", "description": "What it reacts with, degrades into, and how it is stored.", "findings": [ { "id": "incompatibilities", "name": "Incompatibilities and degradation", "description": "What must not meet it, and what it becomes over time.", "questions": [ { "id": "incompatibilities-q01", "text": "What is DL-amphetamine incompatible with, and what does it degrade into under storage?", "kind": "definition" }, { "id": "incompatibilities-q02", "text": "What storage and handling does that require, and who is competent to do it?", "kind": "action" } ] } ] } ] }, { "id": "hazard-and-regulation", "name": "Hazard classification and regulation", "description": "How DL-amphetamine can harm, and what the law says about holding and moving it.", "rationale": "A substance model without its hazard class and its regulatory identity is unusable in exactly the situations that matter.", "layers": [ { "id": "hazard-class", "name": "Hazard classification", "description": "Classified hazards, exposure limits and protective measures.", "findings": [ { "id": "classified-hazards", "name": "Classified hazards and limits", "description": "The classification, the scheme it belongs to, and the limits set.", "questions": [ { "id": "classified-hazards-q01", "text": "How is DL-amphetamine classified for hazard, under which scheme, and what exposure limits apply?", "kind": "definition" }, { "id": "classified-hazards-q02", "text": "What protection does handling require, and what must an agent refuse to do without it?", "kind": "action" } ] } ] }, { "id": "regulatory-identity", "name": "Regulatory identity and control", "description": "Registration, restriction and transport rules by jurisdiction.", "findings": [ { "id": "controls", "name": "Controls and jurisdiction", "description": "Where it is restricted and what the restriction attaches to.", "questions": [ { "id": "controls-q01", "text": "Which registrations, restrictions or transport rules cover DL-amphetamine, and where?", "kind": "provenance" }, { "id": "controls-q02", "text": "Does the control attach to the substance, its concentration, or its intended use?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a DL-amphetamine came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a DL-amphetamine and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a DL-amphetamine is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a DL-amphetamine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a DL-amphetamine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a DL-amphetamine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 9, "layers": 20, "findings": 22, "questions": 60 } } } }